Compare VTSI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | RLYB |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1M | 44.6M |
| IPO Year | 1999 | 2021 |
| Metric | VTSI | RLYB |
|---|---|---|
| Price | $3.76 | $8.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 50.1K | ★ 103.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $185,971.00 | ★ $858,000.00 |
| Revenue This Year | $28.39 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $189.00 | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $3.55 | $0.22 |
| 52 Week High | $7.47 | $11.49 |
| Indicator | VTSI | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 52.93 |
| Support Level | N/A | $0.50 |
| Resistance Level | $4.68 | $11.49 |
| Average True Range (ATR) | 0.25 | 0.65 |
| MACD | -0.07 | -0.33 |
| Stochastic Oscillator | 18.62 | 25.92 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.